 Connection
Nanette Santoro to Thiadiazoles
This is a "connection" page, showing publications Nanette Santoro has written about Thiadiazoles.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.681 |
|
|
|
-
Santoro N, Nappi RE, Neal-Perry G, English M, King DD, Yamaguchi Y, Ottery FD. Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2). Menopause. 2024 Apr 01; 31(4):247-257.
Score: 0.886
-
Santoro N. Neurokinin receptor antagonists as potential nonhormone treatments for vasomotor symptoms. Menopause. 2024 Oct 01; 31(10):923-925.
Score: 0.228
-
Neal-Perry G, Santoro N, Cano A, Nappi RE, Shapiro M, Ottery FD. Totality of evidence refutes neoplasm risk with fezolinetant. Lancet. 2024 05 18; 403(10440):1987-1988.
Score: 0.224
-
Santoro N, Waldbaum A, Lederman S, Kroll R, Fraser GL, Lademacher C, Skillern L, Young J, Ramael S. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause. 2020 12; 27(12):1350-1356.
Score: 0.176
-
Fraser GL, Lederman S, Waldbaum A, Kroll R, Santoro N, Lee M, Skillern L, Ramael S. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020 04; 27(4):382-392.
Score: 0.168
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|